Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.67 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.51 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.51 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Deldeprevir SCHEMBL16020696 | 1.00 | CTSS (0.67) | CTSSADRB3ADRA2BADRA2CCTSB | |
| Deldeprevir SCHEMBL29399555 | 1.00 | CTSS (0.67) | CTSSADRB3ADRA2BADRA2CCTSB | |
| Deldeprevir SCHEMBL16020697 | 1.00 | CTSS (0.67) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL25524203 | 0.96 | CTSS (0.60) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL16927407 | 0.95 | CTSS (0.72) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL13291725 | 0.95 | CTSS (0.72) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL16927409 | 0.95 | CTSS (0.72) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL16927450 | 0.94 | CTSS (0.68) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL13291731 | 0.94 | CTSS (0.68) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL16927447 | 0.94 | CTSS (0.68) | CTSSADRB3ADRA2BADRA2CCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279406-A1 | INDUCIBLE CONTROL OF GENE EXPRESSION | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230241026-A1 | NOVEL DRUG-CONTROLLED SYSTEMS AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-08-03 | — | — | US | disclosed |
| US-11660288-B2 | Drug-controlled systems and uses thereof | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-05-30 | — | — | US | disclosed |
| US-20230159600-A1 | REGULATED SYNTHETIC GENE EXPRESSION SYSTEMS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-05-25 | — | — | US | disclosed |
| US-11572565-B2 | Inducible control of gene expression | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-02-07 | — | — | US | disclosed |
| US-11530246-B2 | Regulated synthetic gene expression systems | TRUSTEES OF BOSTON UNIVERSITY (US) | 2022-12-20 | — | — | US | disclosed |
| US-20220025381-A1 | INDUCIBLE CONTROL OF GENE EXPRESSION | TRUSTEES OF BOSTON UNIVERSITY (US) | 2022-01-27 | — | — | US | disclosed |
| US-11059864-B2 | Chimeric antigen receptor (CAR) modulation | TRUSTEES OF BOSTON UNIVERSITY (US) | 2021-07-13 | — | — | US | disclosed |
| US-20200377564-A1 | REGULATED SYNTHETIC GENE EXPRESSION SYSTEMS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2020-12-03 | — | — | US | disclosed |
| US-20200308234-A1 | CHIMERIC ANTIGEN RECEPTOR (CAR) MODULATION | TRUSTEES OF BOSTON UNIVERSITY (US) | 2020-10-01 | — | — | US | disclosed |
| US-20180055824-A1 | SUBSTITUTED ALIPHANES, CYCLOPHANES, HETERAPHANES, HETEROPHANES, HETERO-HETERAPHANES AND METALLOCENES USEFUL FOR TREATING HCV INFECTIONS | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-03-01 | — | — | US | disclosed |
| US-9592222-B2 | Substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating HCV infections | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-20170007579-A1 | SUBSTITUTED ALIPHANES, CYCLOPHANES, HETERAPHANES, HETEROPHANES, HETERO-HETERAPHANES AND METALLOCENES USEFUL FOR TREATING HCV INFECTIONS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-01-12 | — | — | US | disclosed |
| WO-2016014527-A2 | STABILIZED NUCLEOTIDES FOR MEDICAL TREATMENT | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-01-28 | — | — | WO | disclosed |
| US-20160016986-A1 | STABILIZED NUCLEOTIDES FOR MEDICAL TREATMENT | ACHILLION PHARMACEUTICALS, INC. | 2016-01-21 | — | — | US | disclosed |
| US-20100152103-A1 | 4-AMINO-4-OXOBUTANOYL PEPTIDE CYCLIC ANALOGUES, INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016986-A1 | STABILIZED NUCLEOTIDES FOR MEDICAL TREATMENT | NUDT1, DUT, ADAR | CTSS 3317/4885ADRB3 2748/4885ADRA2B 3461/4885 |
| US-11059864-B2 | Chimeric antigen receptor (CAR) modulation | HAVCR2, CPB1, CTRL | CTSS 53/4885ADRB3 3737/4885ADRA2B 3371/4885 |
| US-20230159600-A1 | REGULATED SYNTHETIC GENE EXPRESSION SYSTEMS | SRRT, BPTF, MYCBP | CTSS 3754/4885ADRB3 4589/4885ADRA2B 4590/4885 |
| US-11660288-B2 | Drug-controlled systems and uses thereof | ATF4, MRPL21, SARS1 | CTSS 1489/4885ADRB3 1925/4885ADRA2B 2727/4885 |
| US-20230241026-A1 | NOVEL DRUG-CONTROLLED SYSTEMS AND USES THEREOF | ATF4, MRPL21, TMPRSS2 | CTSS 1043/4885ADRB3 1423/4885ADRA2B 1976/4885 |
| US-20180055824-A1 | SUBSTITUTED ALIPHANES, CYCLOPHANES, HETERAPHANES, HETEROPHANES, HETERO-HETERAPHANES AND METALLOCENES USEFUL FOR TREATING HCV INFECTIONS | HAVCR2, HCCS, AHR | CTSS 887/4885ADRB3 1259/4885ADRA2B 1110/4885 |
| US-20100152103-A1 | 4-AMINO-4-OXOBUTANOYL PEPTIDE CYCLIC ANALOGUES, INHIBITORS OF VIRAL REPLICATION | VIP, ZC3HAV1, CCL5 | CTSS 2787/4885ADRB3 3270/4885ADRA2B 3266/4885 |
| US-11530246-B2 | Regulated synthetic gene expression systems | SRRT, BPTF, MYCBP | CTSS 3754/4885ADRB3 4589/4885ADRA2B 4590/4885 |
| US-20200308234-A1 | CHIMERIC ANTIGEN RECEPTOR (CAR) MODULATION | HAVCR2, CPB1, CTRL | CTSS 53/4885ADRB3 3737/4885ADRA2B 3371/4885 |
| US-20200377564-A1 | REGULATED SYNTHETIC GENE EXPRESSION SYSTEMS | SRRT, BPTF, MYCBP | CTSS 3754/4885ADRB3 4589/4885ADRA2B 4590/4885 |
| US-20170007579-A1 | SUBSTITUTED ALIPHANES, CYCLOPHANES, HETERAPHANES, HETEROPHANES, HETERO-HETERAPHANES AND METALLOCENES USEFUL FOR TREATING HCV INFECTIONS | HAVCR2, HCCS, AHR | CTSS 887/4885ADRB3 1259/4885ADRA2B 1110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.